Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations
Adeola O Adebayo Michael,Sungjin Ko,Junyan Tao,Akshata Moghe,Hong Yang,Meng Xu,Jacquelyn O Russell,Tirthadipa Pradhan-Sundd,Silvia Liu,Sucha Singh,Minakshi Poddar,Jayvir S Monga,Pin Liu,Michael Oertel,Sarangarajan Ranganathan,Aatur Singhi,Sandra Rebouissou,Jessica Zucman-Rossi,Silvia Ribback,Diego Calvisi,Natalia Qvartskhava,Boris Görg,Dieter Häussinger,Xin Chen,Satdarshan P Monga
DOI: https://doi.org/10.1016/j.cmet.2019.01.002
2019-05-07
Abstract:Based on their lobule location, hepatocytes display differential gene expression, including pericentral hepatocytes that surround the central vein, which are marked by Wnt-β-catenin signaling. Activating β-catenin mutations occur in a variety of liver tumors, including hepatocellular carcinoma (HCC), but no specific therapies are available to treat these tumor subsets. Here, we identify a positive relationship between β-catenin activation, its transcriptional target glutamine synthetase (GS), and p-mTOR-S2448, an indicator of mTORC1 activation. In normal livers of mice and humans, pericentral hepatocytes were simultaneously GS and p-mTOR-S2448 positive, as were β-catenin-mutated liver tumors. Genetic disruption of β-catenin signaling or GS prevented p-mTOR-S2448 expression, while its forced expression in β-catenin-deficient livers led to ectopic p-mTOR-S2448 expression. Further, we found notable therapeutic benefit of mTORC1 inhibition in mutant-β-catenin-driven HCC through suppression of cell proliferation and survival. Thus, mTORC1 inhibitors could be highly relevant in the treatment of liver tumors that are β-catenin mutated and GS positive.